Understanding mechanisms of resistance in myeloma

There are several novel agents and immunotherapies that have changed the treatment landscape of multiple myeloma, yet relapse and disease progression still occur in many patients. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the importance of better understanding mechanisms of resistance to numerous agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), which will be discussed in key sessions at COMy 2022.